Can Americans living in or moving to the EU get GLP-1 weight-loss treatment online?

Yes, Americans who are legally resident in the European Union can access GLP-1 weight-loss treatment through EU-licensed telehealth platforms. A licensed EU physician must assess your medical history, confirm clinical suitability, and issue a prescription. AETHERA Health, an EU-licensed telehealth service, offers this pathway for eligible patients located within the EU. Prescriptions are issued only where clinically appropriate; medication is not sold without a consultation.

Who can access GLP-1 treatment as an American in the EU

To qualify, you must be physically located in an EU member state and registered with a local address or tax identification number. Your clinical eligibility is assessed by an EU-licensed physician based on your BMI, medical history, current medications, and any contraindications. Americans on temporary visas, holiday, or without EU residency cannot access treatment through EU telehealth platforms. If you are relocating to the EU, you should establish residency and local registration before seeking treatment.

How the assessment and prescription process works

The process begins with an online consultation where you complete a detailed health questionnaire covering weight history, metabolic conditions, family history, and current medications. A licensed EU physician reviews your information and may request additional tests such as fasting glucose, kidney function, or thyroid markers depending on your profile. If you meet clinical criteria, the physician issues a prescription valid in the EU. You then collect the medication from a pharmacy (either in-person or via mail order, depending on local regulations). Follow-up consultations monitor your response, side effects, and progress toward your goals.

Cost, timeline, and EU regulatory context

Initial consultations typically cost between 50-150 EUR and take 3-7 days from booking to physician review. Medication costs vary by country and formulation; GLP-1 agonists (semaglutide, tirzepatide) are often partially reimbursed by national health systems if prescribed for type 2 diabetes, but weight-loss-only prescriptions are usually private pay (200-400 EUR per month). EU regulations require that all prescriptions originate from a physician licensed in an EU member state and that patients be resident within the EU. This differs from US telehealth, where Americans can access treatment remotely from any location. Americans moving to the EU should note that prescriptions issued in the US are not automatically valid in EU pharmacies; a new EU prescription is required.

Frequently asked questions

Can I use a US prescription for GLP-1 in EU pharmacies?

No. EU pharmacies require a prescription issued by an EU-licensed physician. You will need a new assessment and prescription from an EU doctor, even if you were previously treated in the US.

What if I'm an American expat but not yet officially resident in an EU country?

Most EU telehealth platforms, including AETHERA, require proof of residency or a local address. If you are in transition, register with local authorities first or contact the platform directly to confirm eligibility.

Are GLP-1 medications covered by EU health insurance?

Coverage depends on your country and reason for treatment. Type 2 diabetes prescriptions are often reimbursed; weight-loss-only treatment is usually private pay. Check your national health system or private insurance policy.

How long does it take to receive medication after approval?

Typically 5-10 business days from prescription issue to pharmacy delivery, depending on your country and whether you collect in-person or by mail.

Can I continue GLP-1 treatment if I move back to the US?

No. EU prescriptions are not valid in the US. You would need to consult a US-licensed physician and obtain a new prescription under US regulations.

If you are an American resident in the EU and interested in GLP-1 treatment, start with a consultation to confirm your eligibility. Begin your assessment with AETHERA.